Abstract
This study was conducted to investigate enhancement of anti-tumor effects of the lentogenic Newcastle disease virus Clone30 strain (NDV rClone30) expressing cytosine deaminase (CD) gene against tumor cells and in murine groin tumor-bearing models. Cytotoxic effects of the rClone30-CD/5-FC on the HepG2 cell line were examined by an MTT method. Anti-tumor activity of rClone30-CD/5-FC was examined in H22 tumor-bearing mice. Compared to the rClone30-CD virus treatment alone, NDV rClone30-CD/5-FC at 0.1 and 1 MOIs exerted significant cytotoxic effects (P<0.05) on HepG2 cells. For treatment of H22 tumor-bearing mice, recombinant NDV was injected together with 5-FC given by either intra-tumor injection or tail vein injection. When 5-FC was administered by intra-tumor injection, survival for the rClone30-CD/5-FC-treated mice was 4/6 for 80 days period vs 1/6 , 0/6 and 0/6 for the mice treated with rClone30-CD, 5-FC and saline alone, respectively. When 5-FC was given by tail vein injection, survival for the rClone30-CD/5-FC-treated mice was 3/6 vs 2/6 , 0/6 and 0/6 for the mice treated with rClone30-CD, 5-FC or saline alone, respectively. In this study, NDV was used for the first time to deliver the suicide gene for cancer therapy. Incorporation of the CD gene in the lentogenic NDV genome together with 5-FC significantly enhances cell death of HepG2 tumor cells in vitro, decreases tumor volume and increases survival of H22 tumor-bearing mice in vivo.
Highlights
Traditional therapies for cancers are nothing less than the radiotherapy and chemotherapy, both of them have many shortcomings and patients are prone to relapse (Zhao et al, 2003)
Our results clearly demonstrate that the incorporation of cytosine deaminase (CD) gene into lentogenic viral genome in combination with 5-FC significantly enhance the anti-tumor activity of the virus
Strain MTH-68 has been shown to have beneficial effects in glioma, astrocytoma and various advanced cancers; 73-T in sarcomas, carcinomas and melanomas; PV701 in various advanced solid tumors, HUJ in glioblastoma and lung tumors; Ulster strain in melanoma, breast and gastrointestinal tumors (Schirrmacher et al, 1999; Fabian et al, 2007)
Summary
Traditional therapies for cancers are nothing less than the radiotherapy and chemotherapy, both of them have many shortcomings and patients are prone to relapse (Zhao et al, 2003). Accumulating evidence indicates that NDV is a powerful anti-tumor agent, and could be alternative way for cancer therapy (Zamarin et al, 2009). Several of the naturally occurring NDV strains have been used in multiple clinical trials against advanced human cancers. Based on their virulence, NDV viruses can be divided into three categories: velogenic (high), mesogenic (medium) and lentogenic (low) groups. Most oncolytic studies are done using either velogenic or mesogenic NDVs (Peeters et al, 1999; Zamarin et al, 2009). The aim of the study intends to enhance the anti-tumor activity of the lentogenic virus by integrating a suicide gene cytosine deaminase into the viral genome (Romer-Oberdorfer et al, 1999; Nakaya et al, 2001)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
